Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company applies science and its global resources to improve health and well-being at every stage of life. Pfizer's diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many consumer health care products. The Company operates in two business segments: Biopharmaceutical and Diversified. Biopharmaceutical includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units. Diversified includes Animal Health products that prevent and treat diseases in livestock and companion animals, and Consumer Healthcare products.
Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. Pfizer's products include Lipitor (atorvastatin, used to lower LDL blood cholesterol); Lyrica (pregabalin, for neuropathic pain/fibromyalgia); Diflucan (fluconazole, an oral antifungal medication); Zithromax (azithromycin, an antibiotic); Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib, an anti-inflammatory drug).
Company Growth (employees)
Key People at Pfizer
Ian C. Read
Frank A. D'Amelio
Laurie J. Olson
Chuck Hill
Rady Johnson
Mikael Dolsten
Doug Lankler
Freda C. Lewis-Hall
Pfizer Office Locations
Pfizer Data and Metrics
Pfizer Financial Metrics
Revenue (FY, 2016) | 52.8 b |
Revenue growth (FY, 2015 - FY, 2016), % | 8% |
Gross profit (FY, 2016) | 40.5 b |
Gross profit margin (FY, 2016), % | 77% |
Net income (FY, 2016) | 7.2 b |
EBIT (FY, 2016) | 7.2 b |
Market capitalization (26-May-2017) | 191.8 b |
Closing share price (26-May-2017) | 32.2 |
- Source: SEC Filings
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 51.6 b | 49.6 b | 48.9 b | 52.8 b |
Revenue growth, % | (4%) | (2%) | 8% | |
Cost of goods sold | 9.6 b | 9.6 b | 9.6 b | 12.3 b |
Gross profit | 42 b | 40 b | 39.2 b | 40.5 b |
Gross profit Margin, % | 81% | 81% | 80% | 77% |
Sales and marketing expense | 14.4 b | 14.1 b | 14.8 b | 14.8 b |
R&D expense | 6.7 b | 8.4 b | 7.7 b | 7.9 b |
Operating expense total | 21 b | 22.5 b | 22.5 b | 22.7 b |
EBIT | 11.4 b | 9.1 b | 7 b | 7.2 b |
EBIT margin, % | 22% | 18% | 14% | 14% |
Pre tax profit | 15.7 b | 12.2 b | 9 b | 8.4 b |
Income tax expense | 4.3 b | 3.1 b | 2 b | 1.1 b |
Net Income | 22.1 b | 9.2 b | 7 b | 7.2 b |
- Source: SEC Filings
| Numbers are in $, USD | Y, 2011 | Y, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|---|---|
Cash | 3.2 b | 10.1 b | 2.2 b | 3.3 b | 3.6 b | |
Inventories | 6.2 b | 5.7 b | ||||
Current Assets | 56.2 b | 57.7 b | 43.8 b | 38.9 b | ||
PP&E | 12.4 b | 11.8 b | ||||
Goodwill | 42.5 b | 42.1 b | 48.2 b | 54.4 b | ||
Total Assets | 172.1 b | 169.3 b | 167.5 b | 171.6 b | ||
Accounts Payable | 3.2 b | 3.4 b | 3.6 b | 4.5 b | ||
Dividends Payable | 1.7 b | 1.7 b | 1.9 b | 1.9 b | ||
Total Debt | 30.5 b | 31.5 b | 28.8 b | |||
Current Liabilities | 23.4 b | 21.6 b | 29.4 b | 31.1 b | ||
Common Stock | 461 m | |||||
Preferred Stock | 24 m | |||||
Additional Paid-in Capital | 77.3 b | 79 b | 81 b | 82.7 b | ||
Retained Earnings | 69.7 b | 72.2 b | 72 b | 71.8 b | ||
Total Equity | 76.6 b | 71.6 b | ||||
Debt to Equity Ratio | 0.4 x | 0.4 x | ||||
Debt to Assets Ratio | 0.2 x | 0.2 x | 0.2 x | |||
Financial Leverage | 2.2 x | 2.4 x |
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 22.1 b | 9.2 b | ||
Accounts Receivable | 940 m | 148 m | 21 m | (134 m) |
Inventories | (538 m) | 175 m | (199 m) | 365 m |
Accounts Payable | 382 m | 297 m | 254 m | 871 m |
Cash From Operating Activities | 17.8 b | 16.9 b | 14.5 b | 15.9 b |
Purchases of PP&E | (1.2 b) | (1.2 b) | (1.4 b) | (1.8 b) |
Cash From Investing Activities | (10.6 b) | (5.7 b) | (3 b) | (7.8 b) |
Short-term Borrowings | (1.2 b) | (8.2 b) | ||
Long-term Borrowings | (4.1 b) | (2.1 b) | (3 b) | (7.7 b) |
Dividends Paid | (6.6 b) | (6.6 b) | (6.9 b) | (7.3 b) |
Cash From Financing Activities | (15 b) | (10 b) | (10.2 b) | (8.9 b) |
Interest Paid | 1.7 b | 1.6 b | 1.3 b | 1.5 b |
Income Taxes Paid | 2.9 b | 2.1 b | 2.4 b | 2.5 b |
| Numbers are in $, USD | Y, 2016 |
|---|---|
Revenue/Employee | 543.5 k |
Pfizer Operating Metrics
| Y, 2014 | Y, 2015 | Y, 2016 | |
|---|---|---|---|
Discovery Projects | 91A | 90B | 96 |
Active Clinical Studies | 448 | 338 | |
Phase III Trials | 22A | 30B | 34 |
Drugs Approved by FDA | 1 |
Pfizer Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Medivation | August 22, 2016 | $14 b |
| Anacor Pharmaceuticals | June 24, 2016 | $5.2 b |
| Allergan | November 23, 2015 | $160 b |
